Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

HCW Biologics (HCWB) EPS (Weighted Average and Diluted) (2021 - 2025)

HCW Biologics (HCWB) has disclosed EPS (Weighted Average and Diluted) for 5 consecutive years, with -$4.5 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EPS (Weighted Average and Diluted) fell 8.96% year-over-year to -$4.5, compared with a TTM value of -$11.4 through Sep 2025, down 126.64%, and an annual FY2024 reading of -$0.77, down 10.0% over the prior year.
  • EPS (Weighted Average and Diluted) was -$4.5 for Q3 2025 at HCW Biologics, up from -$6.79 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at -$0.05 in Q1 2025 and bottomed at -$6.79 in Q2 2025.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$1.01, with a median of -$0.14 recorded in 2021.
  • The sharpest move saw EPS (Weighted Average and Diluted) surged 84.85% in 2022, then plummeted 2850.0% in 2024.
  • Year by year, EPS (Weighted Average and Diluted) stood at -$0.12 in 2021, then plummeted by 35.69% to -$0.16 in 2022, then tumbled by 87.5% to -$0.3 in 2023, then skyrocketed by 80.0% to -$0.06 in 2024, then plummeted by 7400.0% to -$4.5 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for HCWB at -$4.5 in Q3 2025, -$6.79 in Q2 2025, and -$0.05 in Q1 2025.